We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -7.55% | 1.225 | 1.20 | 1.25 | 1.325 | 1.075 | 1.325 | 8,125,769 | 13:30:40 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.23 | 9.31M |
From Apr 2019 to Apr 2024
TIDMSTX
RNS Number : 9250S
Shield Therapeutics PLC
28 June 2018
Shield Therapeutics plc
("Shield" or the "Company")
Result of 2018 Annual General Meeting
London, UK, 28 June 2018. Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company, with a focus on addressing iron deficiency, is pleased to announce that at its Annual General Meeting held on 27 June 2018, shareholders passed all of the ordinary and special resolutions. The full text of each resolution is contained in the Notice of AGM, which is available on the Company's website.
-Ends-
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500 Carl Sterritt, Chief Executive Officer Karl Keegan, Interim Chief Financial Officer Nominated Adviser and Joint Broker Liberum Capital Limited Christopher Britton/Steve Pearce +44 (0)20 3100 2222 Joint Broker Peel Hunt LLP + 44 (0)20 7418 James Steel/Christopher Golden 8900 Financial PR Advisor Consilium Strategic Communications +44 (0)203 709 5700 Mary-Jane Elliott/Matthew Neal
About Shield Therapeutics plc
Shield Therapeutics is a commercial stage pharmaceutical company, delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru(R), for the treatment of all adults with iron deficiency with or without anaemia which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
RAGFKFDPKBKDQAB
(END) Dow Jones Newswires
June 28, 2018 06:56 ET (10:56 GMT)
1 Year Shield Therapeutics Chart |
1 Month Shield Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
